• BRCA2, PARP1 Retention, and RAD51 Filament Protection

  2026-08-24

  The 2025 Nature study identifies a direct mechanism linking PARP inhibitor-induced PARP1 retention to instability of RAD51 filaments at resected DNA. Its biochemical, single-molecule, and cellular data show that full-length BRCA2 prevents PARP1 from occupying DNA and thereby protects homologous recombination, clarifying why BRCA2-deficient cells are particularly vulnerable to PARP inhibition.

• HHV-7 DNA in Ocular Toxoplasmosis: Study Insights

  2026-08-23

  Miyase et al. identified human herpesvirus 7 DNA alongside Toxoplasma gondii DNA in vitreous humor from a patient with recurrent, treatment-refractory ocular toxoplasmosis. The case highlights how compartment-specific multiplex PCR and repeat sampling can reveal a possible viral cofactor in chronic infectious uveitis, while also underscoring the limits of causal inference from a single patient.

• THZ1: Covalent CDK7 Inhibitor Workflow

  2026-08-22

  THZ1 combines nanomolar CDK7 potency with irreversible covalent target engagement, making it valuable for linking transcriptional disruption to proliferation and apoptosis. This practical guide adapts the compound for T-ALL research, cancer biology, and exploratory studies of enhancer-dependent transcription.

• Triacetin: From Adipocyte Assays to Mechanism

  2026-08-21

  Triacetin, also called glyceryl triacetate, is more than a formulation excipient: it can influence lipid metabolism, adipogenesis, and tumor-cell phenotypes. This evidence-focused guide explains how to distinguish direct bioactivity from solvent or vehicle effects when designing biochemical and cell-based assays.

• PX-478 in Prenatal Hypoxia–Related ASD Models

  2026-08-21

  The reference study shows that pharmacological HIF-1α inhibition with PX-478 reduced autism-like behaviors and hippocampal neuronal necrosis in rat offspring exposed to prenatal hypoxia. Its staged postnatal design links behavioral outcomes with HIF-1α, PTEN, VEGF, and toxicity measurements, while also highlighting the importance of treatment timing.

• Dual-Action Inhibitors Reprogram p38α Dephosphorylation

  2026-08-20

  A bioRxiv preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also reshape the activation loop to accelerate its dephosphorylation by WIP1. The structural and biochemical findings introduce a mechanism for improving kinase-inhibitor potency and specificity, while highlighting the need for cellular validation before translation.

• Topotecan: Topoisomerase I Inhibition and Clinical Evidence

  2026-08-20

  The reference review presents topotecan as a water-soluble camptothecin derivative that stabilizes the DNA–topoisomerase I cleavable complex, linking a distinctive mechanism to apoptosis and cytotoxicity. Its pharmacokinetic properties, hematologic toxicity, activity in ovarian and small-cell lung cancers, and potential for combination therapy remain the central practical lessons for cancer research.

• Verapamil in Hypoxia-Driven Urothelial Inflammation

  2026-08-19

  Verapamil ((±)-Verapamil) is more than a cardiovascular reference compound. Evidence from an enzyme-induced hypoxia model positions it as a practical perturbation tool for studying duration-dependent ROS/TXNIP/NLRP3 signaling in urothelial cells, while its calcium-channel and P-glycoprotein pharmacology demands disciplined controls. This article translates those findings into a reproducible experimental and translational strategy.

• 25-Hydroxycholesterol Reprograms Immunosuppressive TAMs

  2026-08-19

  Xiao et al. identify a CH25H–25-hydroxycholesterol circuit that accumulates in tumor-associated macrophage lysosomes and activates AMPKα through GPR155–mTORC1 signaling. The resulting AMPKα–STAT6–ARG1 axis reinforces immunosuppression, while CH25H targeting improves T-cell surveillance and anti-PD-1 responses in tumor models.

• NSC-23766 Rac GTPase Inhibitor Workflows

  2026-08-18

  NSC-23766 is a selective Rac GTPase inhibitor for dissecting Rac1-dependent migration, barrier regulation, apoptosis, and tumor-cell phenotypes. This guide translates its mechanism into dose-matrix, breast cancer, endothelial, and troubleshooting workflows while separating evidence-backed findings from practical starting conditions.

• Mouse Tissue Lysis Kit K1038 Workflow

  2026-08-18

  The Mouse Tissue Lysis Kit K1038 simplifies preparation of mouse tail, toe, and ear lysates for direct PCR-based genotyping and DNA analysis. It is intended for molecular biology research and direct template preparation, not diagnostic, clinical, or medical use.

• MLN2238: Proteasome β5 Subunit Inhibitor

  2026-08-17

  MLN2238 is a reversible proteasome β5 subunit inhibitor with nanomolar activity against the chymotrypsin-like site. Its research value spans multiple myeloma research, lymphoma research, apoptosis studies, and proteotoxic-stress signaling, including the ROS–JNK–CREB pathway.

• Acetylspiramycin: From Biosynthesis to Assay Design

  2026-08-16

  Acetylspiramycin, or Spiramycin B, is more than a macrolide antibiotic: its defined chemical identity makes it a useful probe for connecting ribosomal pharmacology, antimicrobial resistance research, and host-response studies. This article translates biosynthetic evidence into practical assay-design decisions.

• MK-1775: Rethinking Wee1 Checkpoint Strategy

  2026-08-15

  A translational framework for using MK-1775 to connect Wee1 biology, checkpoint abrogation, response measurement, and p53-deficient tumor research.

• Tamsulosin and Postoperative Urinary Retention

  2026-08-15

  A systematic review and meta-analysis of 23 randomized controlled trials found that perioperative Tamsulosin significantly reduced postoperative urinary retention and improved maximum urinary flow rate. The study’s value lies in isolating evidence for one α1-adrenergic antagonist while clarifying which postoperative outcomes were and were not improved.

452 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page